Reports Summarize Non-Alcoholic Fatty Liver Disease Research from University of Texas Health Science Center San Antonio (Does Rapamycin Treatment Alter Age-Associated Changes in Liver Proteome Profile of a Unique Non-Human Primate Model?).

A recent study conducted at the University of Texas Health Science Center in San Antonio explored the effects of rapamycin treatment on age-related changes in the liver proteome profile of a non-human primate model, the common marmoset. The researchers found that the liver proteome of old marmosets treated with rapamycin differed from that of young untreated marmosets or old untreated marmosets. Specifically, rapamycin treatment increased levels of the enzyme ceramidase, which is involved in the breakdown of ceramides. Ceramides have been linked to the development of non-alcoholic fatty liver disease (NAFLD). The study also identified changes in other proteins related to NAFLD. Further analysis is being conducted to better understand the pathways involved in age-associated hepatic fat accumulation. The research was supported by grants from the National Institute on Aging. [Extracted from the article]